Cell Therapy Manufacturing Market- Strategies for Pricing, Cost Control, Reimbursement, Distribution, & More

MarketResearchReports.Biz adds “Global Cell Therapy Manufacturing Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Cell Therapy Manufacturing and the growth estimates for the forecasted period.

Traditionally, one of the major issues with commercializing cell therapy products has been manufacturing bottlenecks. The heterogeneous nature of cell therapy products has introduced manufacturing complexity and regulatory concerns, as well as scale-up complexities that are not present within traditional pharmaceutical manufacturing. Furthermore, much of cell therapy manufacturing now involves patient-specific cell therapies, where cells for an individual patient are processed one batch at a time.

Request Sample Copy of the Report @ https://www.marketresearchreports.biz/sample/sample/1704811

Previously, it was believed that making individual batches of a therapy for a patient would never be a successful commercial model. It was assumed that allogeneic therapies would prevail, because universal cell populations could be prepared in advance to later be prescribed to patients, similar to how drug compounds are administered. Nonetheless, clinical data in support of patient-specific therapy has been compelling, so the pressure is on for the cell therapy industry to manufacture these therapies on a larger scale. Clearly, there are opportunities for the development of both autologous and allogeneic cell therapies, which vary greatly in their manufacturing requirements, routes for patient administration, and cost structures.

While many factors contribute to high pricing associated with cell therapies, a critical factor affecting the pricing of a cell therapy product is the cost of continuously manufacturing the product. To keep a cell therapy product “on market,” manufacturing costs of must be covered and a profit margin achieved. Therefore, great consideration must be given to the variables affecting the costs of goods (COGs) associated with cell therapy manufacturing, as well as strategies for process optimization.

Among cell therapy companies, the pressure for manufacturing process innovation can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise in cell therapy development and manufacturing, such as cell therapy contract and development manufacturing organizations (CDMOs).

Complete Report Details @ https://www.marketresearchreports.biz/reports/1704811/for-cell-therapy-manufacturing-market-research-reports

Currently, there are more than 20 cell therapy CDMO’s specializing in manufacturing and clinical trial support for cell therapy companies, including:WuXiPharmaTech (and its subsidiary WuXiAppTec), Lonza Group, PCT (a Caladrius company), MEDINET, Cell and Gene Therapy Catapult, Brammer Bio, KBI Biopharmaceuticals, PharmaCell, Roslin Cell Therapies, apceth Biopharma, and more.

Benefits of partnering with a cell therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. This report considers the role of cell therapy CDMOs, as well as the importance of in-house manufacturing at cell therapy companies worldwide.

This global strategic report provides detailed analysis oftenleading cell therapy companies worldwide, evaluating the strengths of each company, as well as identifying cell therapy products in development, manufacturing strategies, and partnerships.

Request For TOC Report @ https://www.marketresearchreports.biz/reports/1704811/for-cell-therapy-manufacturing-market-research-reports/toc

These companies include:

ReNeuron

Mesoblast Ltd.

Asterias Biotherapeutics

TiGenix NV

Cellectis

Cynata Therapeutics

Cytori Therapeutics

Astellas Pharma (and Subsidiary Ocata Therapeutics)

Gamida Cell Ltd.

Pluristem Therapeutics

Additionally, the report identifies cell therapy products that have been reviewed and approved by internationally-recognized regulatory agencies, as well as products brought to market in the U.S. with FDA approval. It also specifies which cell therapies have since been pulled from market, due to factors such as low adoption rates, unsuccessful reimbursement strategies, or high cost of manufacturing.

The report analyzes time frames for cell therapy product development, distribution channels, key trends and technologies impacting cell therapy manufacturing, cost control measures, and challenges and considerations affecting with cell therapy manufacturing.

Itprovides an overview of the regulatory environment affecting cell therapy manufacturing in key countries worldwide, evaluating the importance of the recent FDA guidelines for Human Cell and Tissue-based Products (HCT/Ps) and the 21st Century Cures Act, as well as accelerated pathways for cell therapy approvals in Japan, including the:

Act on the Safety of Regenerative Medicine (Law No. 85/2013)

Pharmaceuticals and Medical Device (PMD) Act (Law No. 84/2013)

Based in Washington, DC, BioInformant is first and only market research firm to specialize in the stem cell industry. Unlike other publishers that hire analysts from foreign countries, BioInformant is an American-based company with more than 10 years of experience with tracking the cell therapy market (2006 to present).

BioInformant compiled this global strategic report using primary interviews with more than 50 individuals from across the cell therapy manufacturing industry, including representatives from:

Gamida Cell Ltd. (Dr. Yael Margolin)

Pluristem(YakyYanay, YaronRamati)

CynataTherapeutics (Dr. Paul Wotton)

Accellta (Dr. Itzchak Angel and Eran Cohen)

Stem Cell Medicine Ltd. (Dr. Frida Grynspan)

Minerva Biotechnologies (Dr. Cynthia Bamdad)

RoosterBio (Dr. Jon Rowley)

Universal Cells (Gregory Block)

Many More

It incorporates secondary findings from SEC filings, company websites, press releases, investor presentations, government policy documents (FDA/PMDA), and more.Produced for companies involved with cell therapy product development, this global strategic report offers critical insights into strategies for optimizing modern cell therapy manufacturing.

Companies Mentioned

ReNeuron

Mesoblast Ltd.

Asterias Biotherapeutics

TiGenix NV

Cellectis

Cynata Therapeutics

Cytori Therapeutics

Astellas Pharma, and Subsidiary Ocata Therapeutics

Gamida Cell Ltd.

Pluristem Therapeutics

Organogenesis, Inc. & Novartis AG

Genzyme

MEDIPOST

TiGenix NV

Anterogen

Advanced Tissue Sciences

Vericel

FCB Pharmicell

ChiesiFarmaceutici

NuVasive

GSK

JCR Pharmaceuticals Co. Ltd. (Licensee of Mesoblast Ltd.)

MasTHerCell, Acquired by Orgenesis

PCT, a Caladrius Company (Previously Neostem)

WuXiPharmaTech, Including Subsidiary WuXiAppTech, Inc.

Cell and Gene Therapy Catapult

KBI Biopharma (Acquired Opexa Assets, February 2017)

Brammer Bio (Formed through Merger of Brammer Biopharmaceuticals and Florida Biologix)

Roslin Cell Therapies, a Subsidiary of Roslin Cells

apceth Biopharm

Cognate Bioservices, Inc.

MEDINET Co. Ltd.

PharmaCell, B.V.

The Clinical Trial Company (TCTC)

Miltenyi Bioprocess, the Contract Manufacturing Business of Miltenyi Biotec

Lonza Group, Cell Therapy Manufacturing Unit

Praxis Pharmaceutical

Cellular Therapeutics Ltd. (CTL)

CTI Clinical Trial and Consulting

Eufets GmbH

Fraunhofer Gesellschaft

Cellforcure SASU

Molmed S.p.A.

Cell Therapies Mentioned

Apligraf (Organogenesis, Inc. & Novartis AG)

Carticel (Genzyme)

Cartistem (MEDIPOST)

ChrondoCelect (TiGenix NV)

Cupistem (Anterogen)

Dermagraft (Advanced Tissue Sciences)

Epicel (Vericel)

Hearticellgram-AMI (FCB Pharmicell)

Holoclar (ChiesiFarmaceutici)

Osteocel (NuVasive)

Prochymal (Mesoblast)

Provenge

Strimvelis (GSK)

TEMCELL (JCR Pharmaceuticals Co. Ltd., Licensee of Mesoblast Ltd.)

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact Us

State Tower

90 State Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-621-2074

Website: https://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

This release was published on openPR.